Form 4: Enliven Therapeutics COO Anish Patel Sells Shares Under Pre-Arranged Trading Plan

Enliven Therapeutics' Chief Operating Officer, Anish Patel, sold 6,667 shares of common stock on June 9, 2025, through a pre-arranged Rule 10b5-1 trading plan.

Summary

• Anish Patel, Chief Operating Officer of Enliven Therapeutics, Inc. (ELVN), reported the sale of common stock.
• On June 9, 2025, Mr. Patel sold a total of 6,667 shares of Enliven Therapeutics common stock.
• One transaction involved the sale of 6,607 shares at a weighted average price of $20.3276 per share, with individual trades ranging from $19.96 to $20.85.
• A second transaction involved the sale of 60 shares at a price of $21.16 per share.
• These sales were executed pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024.
• Following these transactions, Mr. Patel beneficially owns 303,309 shares, held indirectly through The Patel / Dong Family Trust Dated August 24, 2017, for which he serves as trustee.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale could be perceived negatively, the fact that it was conducted under a Rule 10b5-1 trading plan significantly mitigates any negative signal, as it indicates a pre-scheduled transaction rather than one based on new, non-public information.

Negatives

• The sale of shares by a high-ranking executive, even if pre-planned, can sometimes be perceived by the market as a lack of confidence, although this is largely mitigated by the Rule 10b5-1 plan.

Risks

• Potential for negative market perception if investors misinterpret the sale as a signal of declining company prospects, despite the existence of a Rule 10b5-1 trading plan.

Future Outlook

NA

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction and does not inherently provide broader industry context. Such filings are common across all industries for publicly traded companies when insiders buy or sell shares.

Related Party Transactions

• The shares sold and beneficially owned are held by The Patel / Dong Family Trust Dated August 24, 2017, for which the reporting person, Anish Patel, serves as trustee. This constitutes an indirect beneficial ownership and a related party holding.

Stakeholder Impact

• Shareholders: May observe a slight negative sentiment due to insider selling, though the 10b5-1 plan largely mitigates concerns about management confidence. The impact is generally minimal for routine planned sales.

Key Dates

Keywords

Enliven Therapeutics, ELVN, Anish Patel, Chief Operating Officer, Insider Sale, Form 4, Rule 10b5-1 Plan, Stock Transaction, Beneficial Ownership